Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 7/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474978 | 0.97 | PDE3B (0.47) | PDE3BPDE3AP2RY12PDE2AGBA1 | |
| SCHEMBL6481683 | 0.93 | PDE3B (0.49) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6526290 | 0.90 | CYP11B1 (0.43) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6475608 | 0.89 | TBXAS1 (0.47) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6484336 | 0.89 | PDE3B (0.50) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6485249 | 0.85 | PDE3B (0.50) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6484254 | 0.85 | PDE3B (0.50) | PDE3BPDE3AP2RY12PDE2ADYRK1A | |
| SCHEMBL6484022 | 0.85 | PDE3B (0.46) | PDE3BPDE3AP2RY12PDE2AAVPR1B | |
| SCHEMBL6484869 | 0.85 | PDE3B (0.49) | PDE3BPDE3AP2RY12PDE2ADYRK1A | |
| SCHEMBL6476128 | 0.84 | HPGD (0.55) | PDE3BPDE3AP2RY12PDE2AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AG (DE) | 2003-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055057-A1 | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutial agents as well as pharmaceutical preparations that contain these derivatives | ARG2, MSR1, ARG1 | PDE3B 210/4885PDE3A 226/4885P2RY12 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.